

Article

Subscriber access provided by Northern Illinois University

# Copper-Catalyzed N-Arylation of 2-Pyridones Employing Diaryliodonium Salts at Room Temperature

Seo-Hee Jung, Dan-Bi Sung, Cho-Hee Park, and Won-Suk Kim

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b01415 • Publication Date (Web): 02 Aug 2016

#### Downloaded from http://pubs.acs.org on August 3, 2016

#### Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# Copper-Catalyzed *N*-Arylation of 2-Pyridones Employing Diaryliodonium Salts at Room Temperature

Seo-Hee Jung<sup>†</sup>, Dan-Bi Sung<sup>†</sup>, Cho-Hee Park, and Won-Suk Kim\*

Department of Chemistry and Nano Science, Ewha Womans University, Seoul 120-750, South Korea.

wonsukk@ewha.ac.kr

**ABSTRACT:** A new and mild synthetic approach for the *N*-arylation of 2-pyridones with diaryliodonium salts has been developed. Most reactions proceed readily at room temperature in the presence of 10 mol % of copper chloride. As a result, a wide range of *N*-aryl pyridine-2-ones were synthesized in yields of 23% to 99%. With this method, antifibrotic drug, Pirfenidone was successfully synthesized in 99% yield within 30 min at room temperature.

#### **INTRODUCTION**

*N*-Aryl pyridine-2-ones are a ubiquitous moiety present in many bioactive compounds and pharmaceutical drugs (Figure 1).<sup>1</sup> Due to their intriguing biological activities such as antifibrotic, anti-inflammatory, anticonvulsant, and sedative activities,<sup>2</sup> several copper-catalyzed coupling reactions for C-N bond formation between 2-pyridones and electrophiles such as aryl boronic acids,<sup>3</sup> aryl stannanes,<sup>4</sup> aryl bismuth,<sup>5</sup> and aryl halides<sup>6</sup> have been previously reported (Scheme 1, eq 1). However, in general, copper-catalyzed coupling reactions for this transformation are relatively slow, requiring more than 12 h due to the low nucleophilicity of 2-pyridones. In particular, the Cu-catalyzed *N*-arylation of 2-pyridones employing aryl halides is generally carried out at elevated temperatures. Therefore, it is still required to develop a mild and expedient method for the preparation of *N*-aryl pyridine 2-ones.

#### Figure 1. N-Aryl pyridine-2-ones containing Drugs.



More stable, electrophilic, and/or less toxic, compared to the corresponding B, Sn, and Bi electrophiles, diaryliodonium salts have been employed as arylating agents in many coupling reactions.<sup>7</sup> In addition, the electrophilicity of diaryliodonium salts can be increased in the presence of a Cu(I) catalyst by forming a reactive aryl-Cu(III) intermediate.<sup>8</sup> Recently, we demonstrated the use of diaryliodonium salts for the synthesis of *N*arylsulfonamides.<sup>9</sup> This reaction was successfully carried out under copper-catalyzed conditions at room temperature. Thus, we hypothesized that the use of diaryliodonium salts could overcome the problems of the current methods and permit the facile production of *N*-aryl pyridine-2-ones at room temperature (Scheme 1, eq 2). Furthermore, to the best of our knowledge, the *N*-arylation of 2-pyridones employing diaryliodonium salts has not been reported.

With these considerations in mind, we report herein the preparation of *N*-aryl pyridine-2-ones using 2-pyridones and diaryliodonium salts at room temperature.

#### Scheme 1. Synthetic Methods for N-Aryl pyridine-2-ones.



#### **RESULTS AND DISCUSSION**

Optimization of the *N*-arylation of 2-pyridones began at room temperature using 2-hydroxypyridine **1** and bis(4-*tert*-butyl)phenyl)iodonium triflate **2** (Table 1). Without a copper catalyst, only a low yield of the desired product **3a** was isolated after 24 h (Table 1, entries 1-2). However, when the reactions were conducted in the presence of either CuI, CuBr, or CuBr-dimethylsulfide complex, the reactions went to completion within 10 min

#### Page 3 of 19

#### The Journal of Organic Chemistry

yielding product **3a** in 96% yield (Table 1, entries 3, 4 and 6). Utilizing CuCl in toluene at room temperature furnished a slightly higher 98% yield in 5 min (Table 1, entry 5). When Cu(II) catalysts such as CuCl<sub>2</sub>, CuBr<sub>2</sub>, CuO, CuSO<sub>4</sub>, and Cu(OAc)<sub>2</sub> were employed, prolonged reaction times and lower yields were observed (Table 1, entries 7-11). In particular, when the reaction was conducted with 5 mol % of CuCl, product **3a** was obtained in a slightly lower 96% yield in 5 min (Table 1, entry 12). Also, when bis(4-(*tert*-butyl)phenyl)iodonium triflate **2** was utilized as a limiting reagent, the desired product **3a** was obtained in 89% yield in 15 min (Table 1, entry 13). Next, we examined the solvent effects for *N*-arylation of 2-pyridone (Table 1, entries 14-15). When the reaction was carried out in THF, no desired product was observed. However, utilizing CuCl in CH<sub>2</sub>Cl<sub>2</sub> at room temperature provided the desired product in 5 min in 95% yield. Furthermore, when different bases were employed, all proved inferior to Et<sub>3</sub>N in terms of yield (Table 1, entries 16-22). Surprisingly, utilizing a bulky base such as DABCO furnished the desired product **3a** in 62% yield along with significant amounts of *O*-arylated product **3aa** (Table 1, entry 22).

# Table 1. Optimization of the N-Arylation Reaction of 2-Pyridone 1 with Bis(4-(*tert*-butyl)phenyl)iodoniumTriflate 2

O NH	+ t-Bu	⊕ <sup>⊖</sup> OTf	Cu cat. <sup>a</sup> (10 mol %) solvent, base		-t-Bu	N t-Bu
1		2		3a		3aa
entry	Cu cat.	base	solvent	temp. (°C)	reaction time	yield of <b>3a</b> (%) <sup>b</sup>
1	no catalyst	Et <sub>3</sub> N	Toluene	25	24 h	13
2	no catalyst	NaH	Toluene	25	24 h	10
3	Cul	Et <sub>3</sub> N	Toluene	25	10 min	96
4	CuBr	Et <sub>3</sub> N	Toluene	25	10 min	96
5	CuCl	Et <sub>3</sub> N	Toluene	25	5 min	98
6	CuBr•SMe <sub>2</sub>	Et <sub>3</sub> N	Toluene	25	10 min	96
7	CuCl <sub>2</sub>	Et <sub>3</sub> N	Toluene	25	24 h	27
8	CuBr <sub>2</sub>	Et <sub>3</sub> N	Toluene	25	24 h	76
9	CuO	Et <sub>3</sub> N	Toluene	25	24 h	90
10	CuSO <sub>4</sub>	Et <sub>3</sub> N	Toluene	25	24 h	33
11	Cu(OAc) <sub>2</sub>	Et <sub>3</sub> N	Toluene	25	24 h	10
12	CuCl <sup>c</sup>	Et <sub>3</sub> N	Toluene	25	5 min	96
13	CuCl <sup>d</sup>	Et <sub>3</sub> N	Toluene	25	15 min	89
14	CuCl	Et <sub>3</sub> N	THF	25	24 h	0
15	CuCl	Et <sub>3</sub> N	CH <sub>2</sub> Cl <sub>2</sub>	25	5 min	95
16	CuCl	K <sub>2</sub> CO <sub>3</sub>	Toluene	25	24 h	53
17	CuCl	KO <sup>t</sup> Bu	Toluene	25	24 h	41
18	CuCl	DIPEA	Toluene	25	5 min	93
19	CuCl	Pyridine	Toluene	25	24 h	14
20	CuCl	K <sub>3</sub> PO <sub>4</sub>	Toluene	25	24 h	70
21	CuCl	$Cs_2CO_3$	Toluene	25	5 min	94
22	CuCl	DABCO	Toluene	25	15 min	62 (21) <sup>e</sup>

Reaction conditions: 0.25 mmol of 2-hydroxypyridine, 0.325 mmol of bis(4-(*tert*-butyl)phenyl)iodonium triflate, 0.50 mmol of base, solvent (0.1 M).

<sup>b</sup> isolated yield.

- <sup>c</sup> 5 mol % of CuCl.
- <sup>d</sup> 0.25 mmol of bis(4-(*tert*-butyl)phenyl)iodonium triflate, 0.325 mmol of 2-hydroxypyridine.
- <sup>e</sup> *O*-arylated product (**3aa**).

With the optimized conditions in hand, we began to investigate the scope of the Cu-catalyzed N-arylation of various 2-pyridones with bis(4-(tert-butyl)phenyl)iodonium triflate 2. As shown in Table 2, most 2-pyridones employed provided the desired products in good-to-excellent yields within 1 h at room temperature. However, when 2-hydroxyquinoline was used as a coupling partner, the desired product 3d was obtained in 99% yield with requiring a longer reaction time, 5 h. It is hypothesized that the increased reaction time is due to the steric hindrance of 2-hydroxyquinoline.<sup>6a</sup> In addition, previous studies have indicated that 2-hydroxypyridine bearing a strong electron-withdrawing nitro group or containing substituents at the 6-position are able to impede Cucatalyzed coupling reactions.<sup>3a, 6b-c</sup> Surprisingly, however, when either 2-hydroxy-5-nitropyridine or 2-hydroxy-3methyl-5-nitropyridine was respectively employed, the coupled product **3f** and **3g** were obtained in 86% and 87% vield in only 5 min, presumably due to the increased electrophilicity of the diaryliodonium salts. Use of halosubstituted-2-pyridones furnished the desired product **3h** and **3i** in excellent yields. Furthermore, other fused or non-fused nitrogen heterocycles proved effective coupling partners under the optimized conditions, furnishing the desired products 3j-3l in yields ranging from 65 to 82%. Next, we studied the use of 2-hydroxy-6-substituted pyridines which are known as unreactive coupling partners for the preparation of N-aryl pyridine-2-ones.<sup>3a, 6b</sup> Interestingly, the use of 2-hydroxy-6-methylpyridine gave a 1.5:1 ratio of O-arylated product **3mm** to N-arylated product 3m. When 2-hydroxy-6-phenylpyridine was used, it showed less reactivity, but provided a 3:1 ratio of Oarylated product **3nn** to *N*-arylated product **3n** in 6 h. Presumably, bulky substituents at the 6-position of 2pyridones hindered coordination at the nitrogen and led to the formation of the O-arylated product as the major product.10





Encouraged by these cross-coupling results, our attention turned to the effect of the counteranions utilizing 3,5dibromo-2-hydroxypyridine 5 and various diphenyliodonium salts 6. As illustrated in Table 3, significant differences in the yield of 7a were observed. The reactions employing diphenyliodonium salts containing OTf, BF<sub>4</sub>, or  $PF_6$  anions provided the coupled product 7a in excellent yields in a short time. However, the use of diphenyliodonium salts having anions OTs, Cl, and Br furnished a lower yield after 24 h.

Table 2. Cu-Catalyzed N-Arylation of Various 2-Pyridones 4 with Bis(4-(tert-butyl)phenyl)iodonium Tri-

t₋Ru

-Bu M

t-Bu

 $O_2$ 

t₋Ru

-Bu

CuCl<sup>a</sup>

toluene, Et<sub>3</sub>N, rt

3c, (96%), 30 min

**3g**, (87%), 5 min

3k, (76%), 20 min

Ρh

t-Bu

**3n**, (24%)<sup>b</sup>, **3nn**, (71%)<sup>b</sup>, 6 h

-Bu

**3d**, (99%)<sup>b</sup>, 5 h

3h, (90%), 5 min

3I, (82%), 1 h

-Bu

*t-*Bu

t-Bu

-Bu

3a-3nn

R

-Bu

Br O NH + Br 5	⊕ <sup>⊕</sup> X ↓↓↓↓ 6	CuCl <sup>a</sup> Et <sub>3</sub> N, toluene, rt	Br O Br 7a
entry	x	time	yield (%) <sup>b</sup>
1	OTf	5 min	90
2	BF <sub>4</sub>	10 min	95
3	PF <sub>6</sub>	10 min	92
4	OTs	24 h	47
5	Cl	24 h	38
6	Br	24 h	15

### Table 3. Effect of the Counteranions for Cu-Catalyzed N-Arylation of 3,5-Dibromo-2-hydroxypyridine 5

<sup>a</sup> Reaction conditions: 0.25 mmol of 3,5-dibromo-2-hydroxypyridine, 0.325 mmol of diphenyliodonium salts, 10 mol % of CuCl, 0.50 mmol of Et<sub>3</sub>N, toluene (0.1 M).

<sup>b</sup> isolated yield.

To further investigate the scope of the Cu-catalyzed *N*-arylation of 2-pyridones, various symmetrical and unsymmetrical diaryliodonium salts were utilized as a coupling partner under the optimized conditions (Table 4). The use of 3,5-dibromo-2-hydroxypyridine **5** and diaryliodonium salts containing electron-neutral, -donating, and -withdrawing groups furnished the desired products **7a-7j** in moderate to excellent yields. In addition, to demonstrate the feasibility of the Cu-catalyzed *N*-arylation of 2-pyridones, the coupling reaction was carried out on a large scale (5.0 mmol), providing **7c** in 99% yield in 5 min. When either the sterically bulky mesityl or trifluoromethoxy- and trifluoromethyl-substituted iodonium salts were used, the reactions were sluggish at room temperature. However, increasing the temperature from rt to 50 °C, furnished full conversion and provided the desired products **7d**, **7e**, and **7i** in 54%, 61% and 53% yield, respectively. Utilizing halo-substituted iodonium triflates at room temperature gave the coupled products **7f-7h** in excellent yields within 1 h. Particularly, when unsymmetric mesityl iodonium triflates, used to transfer the other aryl or heteroaryl group selevtively,<sup>11</sup> were employed at 50 °C, the desired products **7k** and **7l** were obtained in 23% and 73% yields along with the significant amounts of **7d**.





<sup>a</sup> Reaction conditions: 0.25 mmol of 3,5-dibromo-2-hydroxypyridine, 0.325 mmol of diaryliodonium salt, 10 mol % of CuCl, 0.50 mmol of Et<sub>3</sub>N, toluene (0.1 M).

- <sup>b</sup> 5.0 mmol of 3,5-dibromo-2-hydroxypyridine, 6.5 mmol of bis(4-*tert*-butyl)phenyl)iodonium triflate.
- <sup>c</sup> The reaction was conducted at 50 °C.
- <sup>d</sup> 1.5 equiv of diaryliodonium salt.
- <sup>e</sup> Yield of **7d**.

Finally, encouraged by the feasibility of the Cu-catalyzed *N*-arylation of 2-pyridones employing diaryliodonium salts, we next attempted to synthesize Pirfenidone **9**, which has been a widely used anti-fibrotic agent for idiopathic pulmonary fibrosis(IPF) (Scheme 2).<sup>12</sup> Compound **9** was obtained in 99% isolated yield from 2hydroxy-5-methylpyridine **8** and diphenyliodonium hexafluorophosphate in 30 min at room temperature. This new and mild synthetic approach to Pirfenidone is meaningful compared to its previous preparations in terms of yield, reaction time and temperature.<sup>5b, 13</sup>

#### Scheme 2. Synthesis of the Pirfenidone 9



#### CONCLUSION

In conclusion, we have described a new synthetic method for the preparation of *N*-aryl pyridine-2-ones employing 2-pyridones and diaryliodonium salts. The reaction readily proceeds at room temperature, and large scale preparation of **7c** has been successfully conducted to demonstrate the feasibility of our method. The scope of this method has been investigated employing various 2-pyridones and diaryliodonium salts. In particular, 2hydroxypyridines bearing a nitro group proved the effective nucleophile under optimized condition using diaryliodonium salts. In addition, it was found that 2-hydroxypyridines containing substituents at the 6-position can be used to give the *O*-arylated product as the major product. Finally, antifibrotic drug, Pirfenidone was easily synthesized in 99% yield in 30 min employing 2-hydroxy-5-methylpyridine and diphenyliodonium hexafluorophosphate. Further applications and developments based on this method are currently ongoing in our laboratory.

#### 

#### **EXPERIMENTAL SECTION**

#### **General Considerations**

Unless otherwise indicated, all chemical reagents were purchased from commercial suppliers and were used without further purification. All reactions were carried out in oven-dried glassware equipped with a magnetic stir bar. Reactions were monitored by thin layer chromatography (TLC) with 0.25-mm pre-coated silica gel plates (Kieselgel  $60F_{254}$ ). Products were detected by viewing under a UV light, by staining with an anisaldehyde solution composed of acetic acid, sulfuric acid, and MeOH, or by staining with a KMnO<sub>4</sub> solution composed of potassium carbonate, sodium hydroxide, and water. Flash column chromatography was performed on silica gel (70-230 mesh). Yields refer to chromatographically and spectroscopically pure compounds unless otherwise noted. <sup>1</sup>H and <sup>13</sup>C spectra were recorded on a 300 MHz NMR spectrometer. Chemical shifts are reported as  $\delta$  values relative to internal SiMe<sub>4</sub> ( $\delta$  0.00 for <sup>1</sup>H) or chloroform ( $\delta$  77.0 for <sup>13</sup>C) or DMSO-*d*<sub>6</sub> ( $\delta$  2.50 for <sup>1</sup>H and  $\delta$  39.5 for <sup>13</sup>C). IR spectra were measured as neat oils and solids on a FT-IR spectrometer. HRMS data were obtained by electron ionization with a double-focusing high-resolution magnetic sector mass analyzer.

#### **Preparation of 2-pyridones**

4-methoxypyridin-2(1H)-one<sup>14a</sup>, 2-methylfuro[3,2-c]pyridin-4(5H)-one<sup>14b</sup>, thieno[2,3-c]pyridin-7(6H)-one<sup>14b</sup> were prepared as according to cited literature procedures.

#### Preparation of diaryliodonium salts

Diphenyliodonium triflate,<sup>15a</sup> diphenyliodonium tetrafluoroborate,<sup>15b</sup> di-*p*-tolyliodonium triflate,<sup>15a</sup> bis(4-(*tert*-butyl)phenyl)iodonium triflate,<sup>15c</sup> dimesityliodonium triflate,<sup>15c</sup> bis(4-(trifluoromethoxy)phenyl)iodonium tetra-fluoroborate,<sup>15d</sup> bis(4-fluorophenyl)iodonium triflate,<sup>15c</sup> bis(4-chlorophenyl)iodonium triflate,<sup>15c</sup> bis(4-bromophenyl)iodonium triflate,<sup>15c</sup> bis(3-(trifluoromethyl)phenyl)iodonium tetrafluoroborate,<sup>15b</sup> mesityl(4-(methoxycarbonyl)phenyl)iodonium triflate,<sup>15e</sup> mesityl(2-chloropyridin-5-yl)iodonium triflate<sup>15f</sup> and mesit-yl(thiophen-3-yl)iodonium triflate<sup>11d</sup> were prepared as according to cited literature procedures.

General procedure I for synthesis of N-Aryl pyridine-2-ones

A 10 mL round bottom flask was charged with diaryliodonium salts (0.325 mmol), CuCl (10 mol %), Et<sub>3</sub>N (0.5 mmol) and the corresponding pyridin-2-one (0.25 mmol). Toluene (2.5 mL) was then added to the flask. The reaction mixture was stirred at room temperature under Ar. After completion of the reaction as monitored by TLC analysis, the solvent was removed *in vacuo* and the residue was purified by flash column chromatography on silica gel to obtain the desired product.

**1-(4-(***tert***-butyl)phenyl)pyridin-2(1***H***)-one (3a) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and pyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (2:1) provided pure <b>3a** (55.7 mg, 0.245 mmol, 98%) as a white solid. m.p: 108-110 °C;  $R_f$  0.15 (hexane/ethyl acetate=2:1); IR (neat) 2957, 1664, 1586, 1524, 1400, 1269, 1127, 838, 761, 592 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.41-7.27 (m, 4H), 6.65 (d, *J* = 9.3 Hz, 1H), 6.22 (t, *J* = 6.7 Hz, 1H), 1.35 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 162.4, 151.3, 139.6, 138.2, 138.1, 126.2, 125.8, 121.7, 105.7, 34.6, 31.2; HRMS-EI: *m/z* 227.1310 [M<sup>+</sup>; calcd. for  $C_{15}H_{17}NO^+$ : 227.1310].

**2-(4-(***tert***-butyl)phenoxy)pyridine (3aa)** General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.325 mmol), DABCO (instead of Et<sub>3</sub>N) and pyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 15 min. Flash chromatography on silica gel using hexane/ethyl acetate (20:1-2:1) provided pure **3a** (35.2 mg, 0.155 mmol, 62%) as a white solid and **3aa** (12.0 mg, 0.053 mmol, 21%) as a color-less oil.  $R_f$  0.64 (hexane/ethyl acetate=10:1); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.17 (dd, *J* = 4.8 Hz and *J* = 2.1 Hz, 1H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.43 (d, *J* = 8.7 Hz, 2H), 7.05 (d, *J* = 9 Hz, 2H), 6.89 (t, *J* = 5.1 Hz, 1H), 6.84 (d, *J* = 8.4 Hz, 1H), 1.31 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  163.6, 151.5, 147.4, 146.9, 139.0, 126.2, 120.2, 118.0, 111.1, 34.1, 31.2; Data are consistent with those reported in the literature.<sup>16</sup>

**1-(4-(***tert***-butyl)phenyl)-5-methylpyridin-2(1***H***)-one (3b) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 5-methylpyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 30 min. Flash chromatography on silica gel using hexane/ethyl acetate (2:1) provided pure <b>3b** (59.1 mg, 0.245 mmol, 98%) as a white solid. m.p: 118-120 °C; R<sub>f</sub> 0.13 (hexane/ethyl acetate=2:1); IR (neat) 3850, 3742, 2957, 2353, 1675, 1526, 1276, 829, 668 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.48 (dd, *J* = 2.0 Hz and *J* = 6.6 Hz, 2H), 7.32-7.22 (m, 3H), 7.11 (s, 1H), 6.60 (d, *J* = 9.3 Hz, 1H), 2.09 (s, 3H), 1.34 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 161.7, 151.1, 142.3, 138.4, 135.5, 126.2, 125.9, 121.3, 114.6, 34.6, 31.2, 16.9; HRMS-EI: *m/z* 241.1465 [M<sup>+</sup>; calcd. for C<sub>16</sub>H<sub>19</sub>NO<sup>+</sup>: 241.1467].

**1-(4-(***tert***-butyl)phenyl)-4-methoxypyridin-2(1***H***)-one (3c) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 4-methoxypyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 30 min. Flash chromatography on silica gel using hexane/ethyl acetate (1:1) provided pure <b>3c** (61.8 mg, 0.240 mmol, 96%) as a white solid. m.p: 118-120 °C;  $R_f$  0.1 (hexane/ethyl acetate=2:1); IR (neat) 3444, 2960, 2348, 1659, 1482, 1347, 1233, 1026, 831, 618 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.48 (dd, *J* = 1.8 Hz and

J = 6.6 Hz, 2H), 7.28 (dd, J = 2.1 Hz and J = 5.7 Hz, 2H), 7.21 (dd, J = 1.5 Hz and J = 6.6 Hz, 1H), 5.98-5.95 (m, 2H), 3.80 (s, 3H), 1.34 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  168.1, 163.9, 151.1, 138.0, 137.8, 126.2, 126.0, 101.0, 97.5, 55.5, 34.6, 31.2; HRMS-EI: m/z 257.1415 [M<sup>+</sup>; calcd. for C<sub>16</sub>H<sub>19</sub>NO<sub>2</sub><sup>+</sup>: 257.1416].

**1-(4-(***tert***-butyl)phenyl)quinolin-2(1***H***)-one (3d) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.375 mmol) and quinolin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 5 h. Flash chromatography on silica gel using hexane/ethyl acetate (2:1) provided pure 3d (68.7 mg, 0.248 mmol, 99%) as a white solid. m.p: 156-158 °C; R\_f 0.22 (hexane/ethyl acetate=2:1); IR (neat) 3442, 3049, 2957, 2349, 1657, 1590, 1450, 1249, 1118, 834, 753, 532 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.76 (d,** *J* **= 9.6 Hz, 1H), 7.61-7.55 (m, 3H), 7.32 (t,** *J* **= 7.9 Hz, 1H), 7.21-7.15 (m, 3H), 6.77 (d,** *J* **= 9.6 Hz, 1H), 6.67 (d,** *J* **= 8.7 Hz, 1H), 1.39 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 162.3, 151.6, 141.2, 139.6, 134.7, 130.0, 128.1, 128.0, 127.1, 122.13, 122.1, 120.2, 116.0, 34.7, 31.3; HRMS-EI:** *m/z* **277.1464 [M<sup>+</sup>; calcd. for C<sub>19</sub>H<sub>19</sub>NO<sup>+</sup>: 277.1467].** 

**Methyl 1-(4-(***tert***-butyl)phenyl)-6-oxo-1,6-dihydropyridine-3-carboxylate (3e)** General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.325 mmol) and methyl 6-oxo-1,6-dihydropyridine-3carboxylate (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (3:1) provided pure 3e (69.9 mg, 0.245 mmol, 98%) as a white solid. m.p: 126-130 °C; R<sub>f</sub> 0.36 (hexane/ethyl acetate=2:1); IR (neat) 3469, 3065, 2959, 1680, 1522, 1445, 1268, 1109, 841, 770, 635 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.24 (dd, *J* = 0.6 Hz and *J* = 2.4 Hz, 1H), 7.91 (dd, *J* = 2.4 Hz and *J* = 9.6 Hz, 1H), 7.54-7.51 (m, 2H), 7.32-7.29 (m, 2H), 6.63 (dd, *J* = 0.6 Hz and *J* = 9.6 Hz, 1H), 3.86 (s, 3H), 1.36 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  164.5, 162.1, 152.0, 143.4, 138.6, 137.4, 126.3, 125.7, 120.4, 109.6, 51.9, 34.6, 31.1; HRMS-EI: *m/z* 285.1362 [M<sup>+</sup>; calcd. for C<sub>17</sub>H<sub>19</sub>NO<sub>3</sub><sup>+</sup>: 285.1365].

**1-(4-(***tert***-butyl)phenyl)-5-nitropyridin-2(1***H***)-one (<b>3f**) General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.325 mmol) and 5-nitropyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (5:1) provided pure **3f** (58.5 mg, 0.215 mmol, 86%) as a white solid. m.p: 182-185 °C;  $R_f$  0.47 (hexane/ethyl acetate=2:1); IR (neat) 3073, 2958, 2349, 1682, 1509, 1339, 1272, 1109, 834, 753, 634 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.67 (d, *J* = 3.0 Hz, 1H), 8.16 (dd, *J* = 3.0 Hz and *J* = 10.2 Hz, 1H), 7.56 (d, *J* = 6.6 Hz, 2H), 7.32 (d, *J* = 6.6 Hz, 2H), 6.66 (d, *J* = 9.9 Hz, 1H), 1.37 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 161.2, 153.0, 139.9, 136.6, 133.4, 130.9, 126.8, 125.6, 120.4, 34.9, 31.2; HRMS-EI: *m/z* 272.1162 [M<sup>+</sup>; calcd. for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup>: 272.1161].

1-(4-(*tert*-butyl)phenyl)-3-methyl-5-nitropyridin-2(1*H*)-one (3g) General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.325 mmol) and 3-methyl-5-nitropyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (9:1) provided pure **3g** (62.3 mg, 0.218 mmol, 87%) as a white solid. m.p: 152-154 °C;  $R_f$  0.66 (hexane/ethyl acetate=2:1); IR (neat) 2958, 2349, 1671, 1510, 1341, 1267, 1118, 756, 676 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.57 (d, *J* = 2.7 Hz, 1H), 8.04 (dd, *J* = 1.2 Hz and *J* = 3.0 Hz, 1H), 7.54 (d, *J* = 6.9 Hz, 2H), 7.31 (d, *J* = 6.6 Hz, 2H), 2.25 (s, 3H),

1.36 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  162.1, 152.8, 137.3, 137.0, 130.4, 130.3, 129.9, 126.6, 125.7, 34.8, 31.2, 17.6; HRMS-EI: *m/z* 286.1316 [M<sup>+</sup>; calcd. for C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup>: 286.1317].

**3-bromo-1-(4-(***tert***-butyl)phenyl)pyridin-2(1***H***)-one (3h) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 3-bromopyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (5:1) provided pure <b>3h** (68.9 mg, 0.225 mmol, 90%) as a white solid. m.p: 154-155 °C;  $R_f$  0.43 (hexane/ethyl acetate=2:1); IR (neat) 3448, 2959, 2348, 1660, 1512, 1352, 1265, 1134, 1031, 839, 754, 613 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.79 (dd, *J* = 1.8 Hz and *J* = 7.2 Hz, 1H), 7.50-7.47 (m, 2H), 7.36 (dd, *J* = 2.1 Hz and *J* = 6.9 Hz, 1H), 7.31-7.26 (m, 2H), 6.14 (t, *J* = 7.0 Hz, 1H), 1.35 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  158.6, 151.8, 141.7, 138.1, 137.6, 126.2, 125.7, 117.3, 105.7, 34.7, 31.2; HRMS-EI: *m/z* 305.0412 [M<sup>+</sup>; calcd. for C<sub>15</sub>H<sub>16</sub>BrNO<sup>+</sup>: 305.0415].

**5-bromo-1-(4-(***tert***-butyl)phenyl)pyridin-2(1***H***)-one (3i) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 5-bromopyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 30 min. Flash chromatography on silica gel using hexane/ethyl acetate (10:1) provided pure <b>3i** (72.8 mg, 0.238 mmol, 95%) as a white solid. m.p: 118-120 °C; R<sub>f</sub> 0.79 (hexane/ethyl acetate=2:1); IR (neat) 3058, 2959, 2349, 1670, 1588, 1516, 1272, 834, 743, 634 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.51-7.47 (m, 3H), 7.41 (dd, *J* = 2.7 Hz and *J* = 9.6 Hz, 1H) 7.31-7.25 (m, 2H), 6.57 (dd, *J* = 0.5 Hz and *J* = 9.6 Hz, 1H), 1.34 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 160.8, 151.9, 142.7, 137.9, 137.4, 126.4, 125.7, 122.9, 97.9, 34.7, 31.2; HRMS-EI: *m/z* 305.0414 [M<sup>+</sup>; calcd. for C<sub>15</sub>H<sub>16</sub>BrNO<sup>+</sup>: 305.0415].

**5-(4-(***tert***-butyl)phenyl)-2-methylfuro[3,2-c]pyridin-4(5***H***)-one (3j) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 2-methylfuro[3,2-c]pyridin-4(5***H***)-one (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (2:1) provided pure <b>3j** (45.7 mg, 0.162 mmol, 65%) as a white solid. m.p: 136-138 °C;  $R_f$  0.23 (hexane/ethyl acetate=2:1); IR (neat) 3458, 2959, 2349, 1660, 1512, 1265, 1032, 840, 754, 614 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 7.2 Hz, 1H), 6.60 (s, 1H), 6.52 (d, *J* = 7.5 Hz, 1H), 2.43 (s, 3H), 1.36 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 159.0, 158.6, 154.0, 151.0, 138.5, 133.6, 126.4, 126.1, 117.7, 103.3, 95.7, 34.6, 31.3, 13.7; HRMS-EI: *m/z* 281.1417 [M<sup>+</sup>; calcd. for C<sub>18</sub>H<sub>19</sub>NO<sub>2</sub><sup>+</sup>: 281.1416].

**6-(4-(***tert***-butyl)phenyl)thieno[2,3-c]pyridin-7(6***H***)-one (3k) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and thieno[2,3-c]pyridin-7(6***H***)-one (0.25 mmol), and the reaction was completed in 20 min. Flash chromatography on silica gel using hexane/ethyl acetate (5:1) provided pure <b>3k** (53.8 mg, 0.190 mmol, 76%) as a white solid. m.p: 168-172 °C; R<sub>f</sub> 0.41 (hexane/ethyl acetate=2:1); IR (neat) 3099, 2954, 2350, 1650, 1404, 1274, 1136, 839, 768, 706, 575 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.69 (d, *J* = 5.1 Hz, 1H), 7.49 (d, *J* = 8.7 Hz, 2H), 7.35-7.21 (m, 3H), 7.22 (d, *J* = 7.2 Hz, 1H), 6.73 (d, *J* = 7.2 Hz, 1H), 1.35 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 158.7, 151.0, 147.4, 138.2, 132.7, 131.1, 126.2, 126.1, 125.6, 124.5, 101.7, 34.6, 31.2; HRMS-EI: *m/z* 283.1028 [M<sup>+</sup>; calcd. for C<sub>17</sub>H<sub>17</sub>NOS<sup>+</sup>: 283.1031].

#### The Journal of Organic Chemistry

**2-(4-(***tert***-butyl)phenyl)pyridazin-3(2***H***)-one (3I) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and pyridazin-3(2***H***)-one (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (1:1) provided pure <b>3I** (46.8 mg, 0.205 mmol, 82%) as a white solid. m.p: 140-141 °C;  $R_f$  0.08 (hexane/ethyl acetate=2:1); IR (neat) 3443, 3068, 2956, 2349, 1662, 1583, 1511, 1357, 1139, 1031, 831, 599 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (dd, *J* = 1.8 Hz and *J* = 3.9 Hz, 1H), 7.54-7.46 (m, 4H), 7.22 (dd, *J* = 3.6 Hz and *J* = 9.3 Hz, 1H), 7.05 (dd, *J* = 1.8 Hz and *J* = 9.6 Hz, 1H), 1.34 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  160.1, 151.3, 138.8, 136.5, 131.1, 131.0, 125.8, 124.7, 34.6, 31.2; HRMS-EI: *m/z* 228.1265 [M<sup>+</sup>; calcd. for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sup>+</sup>: 228.1263].

**1-(4-(***tert***-butyl)phenyl)-6-methylpyridin-2(1***H***)-one (<b>3m**) and **2-(4-(***tert***-butyl)phenoxy)-6-methylpyridine (<b>3mm**) General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.325 mmol) and 6-methylpyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 3 h. Flash chromatography on silica gel using hexane/ethyl acetate (20:1-2:1) provided pure **3m** (19.3 mg, 0.080 mmol, 32%) as a white solid and **3mm** (29.6 mg, 0.123 mmol, 49%) as a colorless oil. [**3m**] m.p: 122-124 °C; R<sub>f</sub> 0.1 (hexane/ethyl acetate=2:1); IR (neat) 3074, 2960, 2350, 1662, 1577, 1460, 1258, 1146, 806, 600, 522 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.53-7.49 (m, 2H), 7.29 (q, *J* = 6.7 Hz, 1H), 7.13-7.09 (m, 2H), 6.52 (dd, *J* = 0.6 Hz and *J* = 9.3 Hz, 1H), 6.09 (dd, *J* = 0.9 Hz and *J* = 6.9 Hz, 1H), 1.95 (s, 3H), 1.36 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 164.0, 151.4, 146.7, 139.4, 136.0, 127.0, 126.6, 118.3, 105.8, 34.6, 31.2, 21.5; HRMS-EI: *m/z* 241.1465 [M<sup>+</sup>; calcd. for C<sub>16</sub>H<sub>19</sub>NO<sup>+</sup>: 241.1467]. **[3mm]** R<sub>f</sub> 0.64 (hexane/ethyl acetate=10:1); IR (neat) 3851, 3742, 3054, 2959, 2353, 1583, 1448, 1234, 1018, 791 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.50 (t, *J* = 7.8 Hz, 1H), 7.41-7.35 (m, 2H), 7.08-7.02 (m, 2H), 6.84 (d, *J* = 7.2 Hz, 1H), 6.53 (d, *J* = 8.4 Hz, 1H), 2.47 (s, 3H), 1.33 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 163.4, 157.6, 152.1, 147.1, 139.4, 126.5, 120.1, 117.7, 107.1, 34.3, 31.4, 24.1; HRMS-EI: *m/z* 241.1463 [M<sup>+</sup>; calcd. for C<sub>16</sub>H<sub>19</sub>NO<sup>+</sup>: 241.1467].

**1-(4-(***tert***-butyl)phenyl)-6-phenylpyridin-2(1***H***)-one (<b>3n**) and **2-(4-(***tert***-butyl)phenoxy)-6-phenylpyridine (<b>3nn**) General procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (0.375 mmol) and 6-phenylpyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 6 h. Flash chromatography on silica gel using hexane/ethyl acetate (20:1-2:1) provided pure **3n** (18.2 mg, 0.060 mmol, 24%) as a white solid and **3nn** (53.9 mg, 0.178 mmol, 71%) as a colorless oil. **[3n]** m.p: 144-148 °C; R<sub>*f*</sub> 0.14 (hexane/ethyl acetate=2:1); IR (neat) 3054, 2958, 2349, 1666, 1542, 1389, 1261, 1011, 759, 607 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.43 (q, *J* = 6.6 Hz, 1H), 7.27-7.22 (m, 2H), 7.18-7.09 (m, 3H), 7.07-7.03 (m, 2H), 6.99-6.96 (m, 2H), 6.68 (dd, *J* = 1.2 Hz and *J* = 9.3 Hz, 1H), 6.25 (dd, *J* = 1.2 Hz and *J* = 6.9 Hz, 1H), 1.23 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 163.4, 150.8, 149.9, 139.3, 135.8, 135.6, 128.9, 128.3, 128.2, 127.7, 125.6, 120.0, 107.7, 34.5, 31.2; HRMS-EI: *m/z* 303.1620 [M<sup>+</sup>; calcd. for C<sub>21</sub>H<sub>21</sub>NO<sup>+</sup>: 303.1623]. **[3nn]** R<sub>*f*</sub> 0.75 (hexane/ethyl acetate=10:1); IR (neat) 3435, 2348, 1636, 1440, 1242, 753, 539 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.95 (dd, *J* = 1.8 Hz and *J* = 8.1 Hz, 2H), 7.70 (t, *J* = 8.1 Hz, 1H) 7.47-7.35 (m, 6H), 7.17-7.11 (m, 2H), 6.73 (d, *J* = 8.1 Hz, 1H), 1.35 (s, 9H); <sup>13</sup>C NMR (75 MHz,

CDCl<sub>3</sub>)  $\delta$  163.6, 155.6, 151.8, 147.2, 140.0, 138.4, 129.0, 128.5, 126.8, 126.3, 120.4, 114.5, 109.0, 34.3, 31.4; HRMS-EI: *m/z* 303.1625 [M<sup>+</sup>; calcd. for C<sub>21</sub>H<sub>21</sub>NO<sup>+</sup>: 303.1623].

**3,5-dibromo-1-phenylpyridin-2(1***H***)-one (7a)** General procedure I was used employing diphenyliodonium tetrafluoroborate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 10 min. Flash chromatography on silica gel using hexane/ethyl acetate (5:1) provided pure **7a** (78.1 mg, 0.237 mmol, 95%) as a white solid. m.p: 122-124 °C;  $R_f$  0.4 (hexane/ethyl acetate=2:1); IR(neat) 3850, 3741, 3061, 2353, 1665, 1589, 1504, 1338, 1259, 857, 709 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (d, *J* = 2.4 Hz, 1H), 7.51-7.42 (m, 4H), 7.37-7.34 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  157.3, 144.1, 140.0, 137.1, 129.4, 129.1, 126.2, 118.3, 96.9; HRMS-EI: *m/z* 326.8893 [M<sup>+</sup>; calcd. for C<sub>11</sub>H<sub>7</sub>Br<sub>2</sub>NO<sup>+</sup>: 326.8894].

**3,5-dibromo-1-**(*p*-tolyl)pyridin-2(1*H*)-one (7b) General procedure I was used employing di-*p*-tolyliodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (9:1) provided pure 7b (83.2 mg, 0.243 mmol, 97%) as a white solid. m.p: 134-136 °C;  $R_f$  0.62 (hexane/ethyl acetate=2:1); IR(neat) 3447, 2348, 1664, 1592, 1509, 1261, 845, 748 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.86 (d, *J* = 2.4 Hz, 1H), 7.48 (d, *J* = 2.7 Hz, 1H), 7.30-7.21 (m, 4H), 2.40 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  157.4, 144.0, 139.2, 137.6, 137.3, 130.0, 125.9, 118.3, 96.7, 21.1; HRMS-EI: *m/z* 340.9052 [M<sup>+</sup>; calcd. for C<sub>12</sub>H<sub>9</sub>Br<sub>2</sub>NO<sup>+</sup>: 340.9051].

**3,5-dibromo-1-(4-(***tert***-butyl)phenyl)pyridin-2(1***H***)-one (7c) General procedure I was used employing bis(4-(***tert***-butyl)phenyl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 5 min. Flash chromatography on silica gel using hexane/ethyl acetate (10:1) provided pure 7c (94.3 mg, 0.245 mmol, 98%) as a white solid. For the large scale synthesis**, general procedure I was used employing bis(4-(*tert*-butyl)phenyl)iodonium triflate (6.5 mmol) and 3,5-dibromopyridin-2(1*H*)-one (5.0 mmol), and the reaction was completed in 5 min as 99% yield (4.96 mmol, 1.91 g). m.p: 132-134 °C; R<sub>f</sub> 0.78 (hexane/ethyl acetate=2:1); IR (neat) 3058, 2959, 2414, 1668, 1509, 1353, 1260, 1106, 850, 751, 544 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.86 (d, *J* = 2.7 Hz, 1H), 7.51-7.48 (m, 3H), 7.28 (d, *J* = 9.0 Hz, 2H), 1.34 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  157.5, 152.3, 144.0, 137.5, 137.3, 126.4, 125.6, 118.3, 96.8, 34.8, 31.2; HRMS-EI: *m/z* 382.9521 [M<sup>+</sup>; calcd. for C<sub>15</sub>H<sub>15</sub>Br<sub>2</sub>NO<sup>+</sup>: 382.9520].

**3,5-dibromo-1-mesitylpyridin-2(1***H***)-one (7d)** General procedure I was used employing dimesityliodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol) at 50 °C, and the reaction was completed in 5 h . Flash chromatography on silica gel using hexane/ethyl acetate (7:1) provided pure **7d** (50.1 mg, 0.135 mmol, 54%) as a white solid. m.p: 128-130 °C;  $R_f$  0.56 (hexane/ethyl acetate=2:1); IR(neat) 3854, 3742, 2354, 1664, 1264, 859, 756, 680 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.90 (d, *J* = 2.7 Hz, 1H), 7.26 (d, *J* = 2.7 Hz, 1H), 6.97 (s, 2H), 2.31 (s, 3H), 2.05 (s, 6H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  156.8, 144.3, 139.2, 137.2, 136.1, 134.0, 129.4, 118.6, 96.9, 21.0, 17.6; HRMS-EI: *m/z* 368.9362 [M<sup>+</sup>; calcd. for C<sub>14</sub>H<sub>13</sub>Br<sub>2</sub>NO<sup>+</sup>: 368.9364].

**3,5-dibromo-1-(4-(trifluoromethoxy)phenyl)pyridin-2(1***H***)-one (7e) General procedure I was used employing bis(4-(trifluoromethoxy)phenyl)iodonium tetrafluoroborate (0.325 mmol) and 3,5-dibromopyridin-2(1***H***)-one (0.25 mmol) at 50 °C, and the reaction was completed in 6 h. Flash chromatography on silica gel using hexane/ethyl acetate (10:1) provided pure 7e (63.0 mg, 0.153 mmol, 61%) as a white solid. m.p: 104-106 °C; R\_f 0.8 (hexane/ethyl acetate=2:1); IR(neat) 3851, 3741, 3447, 2353, 1662, 1516, 1258, 852, 751, 670 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) \delta 7.88 (d,** *J* **= 2.7 Hz, 1H), 7.49 (d,** *J* **= 2.7 Hz, 1H), 7.46-7.40 (m, 2H), 7.34 (d,** *J* **= 8.4 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) \delta 157.2, 149.2 (d,** *J* **= 1.8 Hz) 144.4, 138.2, 136.6, 128.0, 121.8, 120.3 (q,** *J* **= 256.7Hz), 118.5, 97.3; HRMS-EI:** *m/z* **410.8718 [M<sup>+</sup>; calcd. for C<sub>12</sub>H<sub>6</sub>Br<sub>2</sub>F<sub>3</sub>NO<sub>2</sub><sup>+</sup>: 410.8717].** 

**3,5-dibromo-1-(4-fluorophenyl)pyridin-2(1***H***)-one (7f) General procedure I was used employing bis(4-fluorophenyl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (5:1) provided pure 7f (73.7 mg, 0.212 mmol, 85%) as a white solid. m.p: 148-150 °C; R\_f 0.44 (hexane/ethyl acetate= 2:1); IR(neat) 3851, 3742, 3434, 2353, 1656, 1511, 1222, 833, 677, 517 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) \delta 7.87 (d,** *J* **= 2.7 Hz, 1H), 7.48 (d,** *J* **= 2.4 Hz, 1H), 7.38-7.32 (m, 2H), 7.17 (t,** *J* **= 8.5 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) \delta 162.4 (d,** *J* **= 248.3 Hz) 157.3 144.2, 136.9, 135.9, 128.1 (d,** *J* **= 8.8 Hz), 118.3, 116.4 (d,** *J* **= 23 Hz), 97.1; HRMS-EI:** *m/z* **344.8802 [M<sup>+</sup>; calcd for C<sub>11</sub>H<sub>6</sub>Br<sub>2</sub>FNO<sup>+</sup>: 344.8800].** 

**3,5-dibromo-1-(4-chlorophenyl)pyridin-2(1***H***)-one (7g) General procedure I was used employing bis(4chlorophenyl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1***H***)-one (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (6:1) provided pure 7g (84.5 mg, 0.233 mmol, 93%) as a white solid. m.p: 160-162 °C; R\_f 0.5 (hexane/ethyl acetate=2:1); IR(neat) 3852, 3743, 2354, 1651, 1566, 1234, 1085, 833, 733; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) \delta 7.87 (d,** *J* **= 2.4 Hz, 1H), 7.47-7.44 (m, 3H), 7.33-7.29 (m, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) \delta 157.2, 144.3, 138.3, 136.6, 135.1, 129.6, 127.6, 118.4, 97.2; HRMS-EI:** *m/z* **360.8505 [M<sup>+</sup>; calcd. for C<sub>11</sub>H<sub>6</sub>Br<sub>2</sub>ClNO<sup>+</sup>: 360.8505].** 

**3,5-dibromo-1-(4-bromophenyl)pyridin-2(1***H***)-one (7h)** General procedure I was used employing bis(4bromophenyl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 30 min. Flash chromatography on silica gel using hexane/ethyl acetate (9:1) provided pure **7h** (91.8 mg, 0.225 mmol, 90%) as a white solid. m.p: 160-162 °C;  $R_f$  0.6 (hexane/ethyl acetate=2:1); IR(neat) 3854, 3742, 2354, 1659, 1252, 836, 673 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.87 (d, *J* = 2.7 Hz, 1H), 7.63 (d, *J* = 9.0 Hz, 2H), 7.46 (d, *J* = 2.7 Hz, 1H), 7.26 (d, *J* = 9.0 Hz, 2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  157.2, 144.3, 138.9, 136.5, 132.7, 127.9, 123.2, 118.5, 97.3; HRMS-EI: *m/z* 404.8002 [M<sup>+</sup>; calcd. for C<sub>11</sub>H<sub>6</sub>Br<sub>3</sub>NO<sup>+</sup>: 404.7999].

**3,5-dibromo-1-(3-(trifluoromethyl)phenyl)pyridin-2(1***H***)-one (7i) General procedure I was used employing bis(3-(trifluoromethyl)phenyl)iodonium tetrafluoroborate (0.375 mmol) and 3,5-dibromopyridin-2(1***H***)-one (0.25 mmol) at 50 ^{\circ}C, and the reaction was completed in 3 h. Flash chromatography on silica gel using hexane/ethyl acetate (9:1) provided pure 7i (52.6 mg, 0.132 mmol, 53%) as a white solid. m.p: 128-130 ^{\circ}C; R<sub>f</sub> 0.67 (hexane/ethyl acetate=2:1); IR(neat) 3852, 3740, 3445, 2353, 1651, 1542, 1329, 1128, 667 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, 15** 

CDCl<sub>3</sub>)  $\delta$  7.90 (d, J = 2.4 Hz, 1H), 7.75-7.57 (m, 4H), 7.50 (d, J = 2.7 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  157.2, 144.5, 140.3, 136.3, 132.1 (q, J = 33.1 Hz), 130.2, 129.8, 126.0 (d, J = 3.6 Hz), 123.5 (d, J = 3.8 Hz), 123.2 (d, J = 271.1 Hz), 118.5, 97.6; HRMS-EI: m/z 394.8769 [M<sup>+</sup>; calcd. for C<sub>12</sub>H<sub>6</sub>Br<sub>2</sub>F<sub>3</sub>NO<sup>+</sup>: 394.8768].

Methyl 4-(3,5-dibromo-2-oxopyridin-1(2*H*)-yl)benzoate (7j) General procedure I was used employing mesityl(4-(methoxycarbonyl)phenyl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 6 h. Flash chromatography on silica gel using hexane/ethyl acetate (3:1) provided pure 7j (62.9 mg, 0.163 mmol, 65%) as a pale yellow solid. m.p: 183-185 °C; R<sub>f</sub> 0.3 (hexane/ethyl acetate=2:1); IR(neat) 3854, 3743, 2354, 1659, 1561, 1281, 1105, 862, 723 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.17 (dd, *J* = 1.8 Hz and *J* = 6.9 Hz, 2H), 7.89 (d, *J* = 2.4 Hz, 1H), 7.51-7.46 (m, 3H), 3.95 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 165.8, 157.1, 144.4, 143.5, 136.3, 130.83, 130.77, 126.3, 118.6, 97.5, 52.5; HRMS-EI: *m/z* 384.8948 [M<sup>+</sup>; calcd. for C<sub>13</sub>H<sub>9</sub>Br<sub>2</sub>NO<sub>3</sub><sup>+</sup>: 384.8949].

**3,5-dibromo-6'-chloro-2***H*-[**1,3'-bipyridin**]-**2-one** (**7k**) General procedure I was used employing mesityl(2chloropyridin-5-yl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol) at 50 °C, and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (7:1–3:1) provided pure **7k** (21.0 mg, 0.058 mmol, 23%) as a white solid and **7d** (59.3 mg, 0.160 mmol, 64%) as a white solid. m.p: 168-172 °C;  $R_f$  0.36 (hexane/ethyl acetate=2:1); IR(neat) 3851, 3738, 3445, 2353, 1643, 751, 665 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  8.57 (d, *J* = 2.6 Hz, 1H), 8.28 (d, *J* = 2.5 Hz, 1H), 8.18 (d, *J* = 2.6 Hz, 1H), 8.06 (dd, *J* = 2.8 Hz and *J* = 8.5 Hz, 1H), 7.72 (d, *J* = 8.5 Hz, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  157.2, 150.4, 148.5, 145.4, 139.1, 138.8, 136.5, 125.0, 116.8, 97.1; HRMS-EI: *m*/z 361.8456 [M<sup>+</sup>; calcd. for C<sub>10</sub>H<sub>5</sub>Br<sub>2</sub>CIN<sub>2</sub>O<sup>+</sup>: 361.8457].

**3,5-dibromo-1-(thiophen-3-yl)pyridin-2(1***H***)-one (7l)** General procedure I was used employing mesityl(thiophen-3-yl)iodonium triflate (0.325 mmol) and 3,5-dibromopyridin-2(1*H*)-one (0.25 mmol), and the reaction was completed in 1 h. Flash chromatography on silica gel using hexane/ethyl acetate (9:1–7:1) provided pure 7l (61.1 mg, 0.182 mmol, 73%) as a pale yellow solid and 7d (11.1 mg, 0.030 mmol, 12%) as a white solid. m.p: 138-140 °C;  $R_f$  0.67 (hexane/ethyl acetate=2:1); IR(neat) 3854, 3742, 2354, 1660, 1589, 1403, 1264, 859, 727 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.84 (s, 1H), 7.59 (s, 1H), 7.47 (s, 1H), 7.38 (s, 1H), 7.22 (d, *J* = 4.5 Hz, 1H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  156.8, 143.7, 137.4, 136.6, 125.9, 124.3, 120.4, 118.2, 97.0; HRMS-EI: *m/z* 332.8459 [M<sup>+</sup>; calcd. for C<sub>9</sub>H<sub>5</sub>Br<sub>2</sub>NOS<sup>+</sup>: 332.8459].

#### Procedure for synthesis of Pirfenidone 9 (5-methyl-1-phenylpyridine-2-(1H)-one)

A 10 mL round bottom flask was charged with diphenyliodonium hexafluorophosphate (0.325 mmol), CuCl (10 mol %), Et<sub>3</sub>N (0.5 mmol) and 5-methylpyridin-2(1*H*)-one (0.25 mmol). Toluene (2.5 mL) was then added to the flask. The reaction mixture was stirred at room temperature under Ar. After 30 min, the solvent was removed *in vacuo* and the residue was purified by flash column chromatography on silica gel using dichloro-

methane/methanol (30:1) provided pure Pirfenidone **9** (45.8 mg, 0.247 mmol, 99%) as a white solid.  $R_f$  0.08 (hexane/ethyl acetate=2:1); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.50-7.44 (m, 2H), 7.43-7.35 (m, 3H), 7.26 (dd, J = 2.8 Hz and J = 9.3 Hz, 1H), 7.12-7.10 (m, 1H), 6.60 (d, J = 9.6 Hz, 1H), 2.10 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  161.6, 142.5, 141.0, 135.2, 129.2, 128.2, 126.5, 121.4, 114.7, 16.9; Data are consistent with those reported in the literature.<sup>5b</sup>

#### ASSOCIATED CONTENT

#### Supporting Information

Copies of <sup>1</sup>H and <sup>13</sup>C spectra for all novel compounds prepared. This material is available free of charge via the Internet at

http://pubs.acs.org.

#### AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail: wonsukk@ewha.ac.kr

#### **Author Contributions**

<sup>†</sup> S.-H. Jung and D.-B. Sung contributed equally to this work.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENT

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) (NRF-

2015R1A1A1A05001334) and the New & Renewable Energy of the Korea Institute of Energy Technology Evaluation and Planning

(KETEP) grant (No. 20133030000210).

#### REFERENCES

- (1) (a) Scudi, J. V.; Reisner, D. B.; Childress, S. J.; Walter, L. US2947755, **1960**. (b) Young, S. D.; Anthony, N. J.; Gomez, R. P.; Tran, L. O. WO9828980, **1998**. (c) Moffat, D. C. F. WIPO, WO2007129036 A1, **2007**. (d) Lv, Z.; Sheng, C.; Wang, T.; Zhang, Y.; Liu, J.; Feng, J.; Sung, H.; Zhong, H.; Niu, C.; Li, K. *J. Med. Chem.* **2010**, *53*, 660-668. (e) Hibi, S.; Ueno, K.; Nagato, S.; Kawano, K.; Ito, K.; Norimine, Y.; Takenaka, O.; Hanada, T.; Yonaga, M. J. *Med. Chem.* **2012**, *55*, 10584-10600.
- (2) (a) Azima, H.; Arthurs D.; Silver, A. Am. J. Psychiarty 1961, 118, 159-160. (b) Nakazato, H.; Oku, H.; Yamane, S.; Tsuruta, Y.; Suzuki, R. Eur. J. Pharmacol. 2002, 446, 177-185. (c) Azuma, A. Expert Rev. Respir. Med. 2010, 4, 301-310. (d) Cho, M.; Kopp, J. B. Expert Opin. Investig. Drugs. 2010, 19, 275-283. (e) Schaefer. C. J.; Ruhrmund, D. W.; Pan, L.; Seiwert, S. D.; Kossen, K. Eur. Respir. Rev. 2011, 20, 85-97. (f) Hoppner, A. C.; Fauser S.; Kerling F. Epileptic Disord. 2013, 15, 362-364. (g) Dirani, M.; Nasreddine, W.; Abdulla, F.; Beydoun, A. Epilepsy Behav. Case Rep. 2014, 2, 164-166.
- (3) (a) Mederski, W. W. K. R.; Lefort, M.; Germann, M.; Kux, D. *Tetrahedron* 1999, 55, 12757-12770. (b) Lam, Y. S. P.; Clark, C. G.; Sauber, S.; Adams, J.; Averill, K. M.; Chan, D. M. T.; Combs, A. *Synlett* 2000, 674-676. (c) Lam,

Y. S. P.; Vincent, G.; Clark, C. G.; Deudon, S.; Jadhav, P. K. *Tetrahedron Lett.* **2001**, *42*, 3415-3418. (d) McElhinny, C. J.; Carroll, F. I.; Lewin, A. H. *Synthesis* **2012**, 57-62. (e) Chen, T.; Luo, Y.; Hu, Y.; Yang, B. Lu, W. *Eur. J. Me. Chem.* **2013**, *64*, 613-620.

- (4) (a) Lam, P. Y. S.; Vincent, G.; Bonne, D.; Clark, C. G. *Tetrahedron Lett.* 2002, *43*, 3091-3094. (b) Tsou, H.-R.; Liu, X.; Brinberg, G.; Kaplan, J.; Otteng, M.; Tran, T.; Kutterer, K.; Tang, Z.; Suayan, R. Zask, A.; Ravi, M.; Bretz, A.; Grillo, M.; McGinnis, J. P.; Rabindran, S. K.; Ayral-Kaloustian, S.; Mansour, T. S. *J. Med. Chem.* 2009, *52*, 2289-2310.
- (5) (a) Ikegai, K.; Nagata, Y.; Mukaiyama, T. Bull. Chem. Soc. Jpn. 2006, 79, 761-767. (b) Crifar, C.; Petiot, P.; Ahmad, T. Gagnon, A. Chem. Eur. J. 2014, 20, 2755-2760.
- (6) (a) Sugahara, M.; Ukita, T. Chem. Pharm. Bull. 1997, 45, 719-721. (b) Li, C. S.; Dixon, D. D. Tetrahedron Lett. 2004, 45, 4257-4260. (c) Altman, R. A.; Buchwald, S. L. Org Lett. 2007, 9, 643-646 and references cited therein.
- (7) For a recent review, see: (a) Yosimura, A.; Zhdankin, V. V. Chem. Rev. 2016, 116, 3328-3435. (b) Aradi, K.; Tóth, B. L.; Tolnai, G. L.; Novák, Z. Synlett 2016, 27, 1456-1485. (c) Olofsson, B. Top. Curr. Chem. 2016, 373, 135-166 and references cited therein.
- (8) (a) Hickman, A. J.; Sanford, M. S. Nature 2012, 484, 177-185. (b) Casitas, A.; Ribas, X. Chem. Sci. 2013, 4, 2301-2318.
- (9) Moon, S.-Y.; Koh, M.; Rathwell, K.; Jung, S.-H.; Kim, W.-S. Tetrahedron 2015, 71, 1566-1573.
- (10) Chen, T.; Huang, Q.; Luo, Y.; Hu, Y.; Lu, W. Tetrahedron Lett. 2013, 54, 1401-1404.
- (11)(a) Kalayani, D.; Deprez, N. R.; Desai, L. V.; Sanford, M. S. J. Am. Chem. Soc. 2005, 127, 7330-7331. (b) Kuriyama, M.; Hamaguchi, N.; Onomura, O. Chem. Eur. J. 2012, 18, 1591-1594. (c) Malmgren, J.; Santoro, S.; Jalalian, N.; Himo, F.; Olofsson, B. Chem. Eur. J. 2013, 19, 10334-10342. (d) Collins, B. S. L.; Suero, M. G.; Gaunt, M. J. Angew. Chem. Int. Ed. 2013, 52, 5799-5802.
- (12) (a) Raghu, G.; Johnson, W. C.; Lockhart, D.; Mageto, Y. Am. J. Respir. Crit. Care. Med. 1999, 159, 1061-1069. (b) Dosanjh, A. Eur. J. Pharmacol. 2006, 536, 219-222. (c) du Bois, R. M. Nature Rev. Drug. Discov. 2010, 9, 129-140. (d) Richeldi, L.; Yasothan U. Kirkpatrick, P. Nature Rev. Drug. Discov. 2011, 10, 489-490.
- (13)(a) Abd El Kader, K. F.; El Bialy, S. A. A.; El-Ashmawy, M. B.; Boykin, D. W. *Heterocycl. Commun.* 2012, 18, 193-197.
  (b) Taniguchi, T.; Hayashi, K.; Morizawa, Y. WO03014087, 2003.
  (c) Gant, T. G.; Sarshar, S. WO2008157786, 2008.
- (14)(a) Sieburth, S. M.; Lin, C. H.; Rucando, D. J. Org. Chem. 1999, 64, 950-953. (b) Li, L.; Degardin, M.; Lavergne, T.; Malyshev, D. A.; Dhami, K.; Ordoukhanian, P.; Romesberg, F. E. J. Am. Chem. Soc. 2014, 136, 826-829.
- (15)(a) Bielawski, M.; Olofsson, B. Chem. Commun. 2007, 2521-2523. (b) Bielawski, M.; Aili, D.; Olofsson, B. J. Org. Chem. 2008, 73, 4602-4607. (c) Bielawski, M.; Zhu, M.; Olofsson, B. Adv. Synth. Catal. 2007, 349, 2610-2618. (d) Monastyrskyi, A.; Namelikonda, N. K.; Manetsch, R. J. Org. Chem. 2015, 80, 2513-2520. (e) Bedford, R. B.; Webster, R. L.; Mitchell, C. J. Org. Biomol. Chem. 2009, 7, 4853-4857. (f) Nikolaienko, P.; Yildiz, T.; Ruepin, M. Eur. J. Org. Chem. 2013, 15, 5134-5137.
- (16) Londregan, A. T.; Jennings, S.; Wei, L. Org. Lett. 2011, 13, 1840-1843.

## **Table of Contents Graphic**

Θ  $\oplus$ Х R<sup>/</sup>= + R<sup>1<u>1</u></sup>

R = H, EDG, EWG, Aryl, Heteroaryl R<sup>1</sup> = H, EDG, EWG, Heteroaryl X = OTf, BF<sub>4</sub>, OTs, CI, Br, PF<sub>6</sub>

CuCl (10 mol %)

toluene,  $Et_3N$ , rt

27 examples 23-99% yield

